Bellevue Group AG trimmed its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 5.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,430,500 shares of the company’s stock after selling 153,050 shares during the period. Neurocrine […]
Rhenman & Partners Asset Management AB grew its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 13.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 62,000 shares of the company’s stock after acquiring an additional 7,434 shares during the period. Rhenman […]
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective hoisted by UBS Group from $174.00 to $193.00 in a report issued on Tuesday morning, Benzinga reports. UBS Group currently has a buy rating on the stock. Several other equities research analysts have also recently issued reports on NBIX. Needham & Company LLC reaffirmed a […]
Claret Asset Management Corp bought a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,565 shares of the company’s stock, valued at approximately $206,000. Other hedge funds and other […]
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As discussed. | May 19, 2023